Open Access
Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients
Francesca Lombardi
1
,
Simone Belmonti
1
,
Alberto Borghetti
2
,
Arturo Ciccullo
1
,
Gianmaria Baldin
1
,
Roberto Cauda
1, 2
,
Massimiliano Fabbiani
3
,
Simona Di Giambenedetto
1, 2
Publication type: Journal Article
Publication date: 2019-05-04
scimago Q2
wos Q3
SJR: 0.693
CiteScore: 2.6
Impact factor: 1.8
ISSN: 25787489, 25787470
PubMed ID:
31478469
Infectious Diseases
Pharmacology (medical)
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
|
|
|
Journal of Antimicrobial Chemotherapy
2 publications, 16.67%
|
|
|
Open Forum Infectious Diseases
2 publications, 16.67%
|
|
|
Journal of Acquired Immune Deficiency Syndromes
1 publication, 8.33%
|
|
|
Diagnostics
1 publication, 8.33%
|
|
|
Frontiers in Immunology
1 publication, 8.33%
|
|
|
HIV Medicine
1 publication, 8.33%
|
|
|
Journal of Infectious Diseases
1 publication, 8.33%
|
|
|
HIV/AIDS - Research and Palliative Care
1 publication, 8.33%
|
|
|
Immunity and Ageing
1 publication, 8.33%
|
|
|
AIDS Research and Treatment
1 publication, 8.33%
|
|
|
1
2
|
Publishers
|
1
2
3
4
5
|
|
|
Oxford University Press
5 publications, 41.67%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 8.33%
|
|
|
MDPI
1 publication, 8.33%
|
|
|
Frontiers Media S.A.
1 publication, 8.33%
|
|
|
Wiley
1 publication, 8.33%
|
|
|
Taylor & Francis
1 publication, 8.33%
|
|
|
Springer Nature
1 publication, 8.33%
|
|
|
Hindawi Limited
1 publication, 8.33%
|
|
|
1
2
3
4
5
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
12
Total citations:
12
Citations from 2024:
3
(25%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Lombardi F. et al. Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients // HIV Research and Clinical Practice. 2019. Vol. 20. No. 3. pp. 92-98.
GOST all authors (up to 50)
Copy
Lombardi F., Belmonti S., Borghetti A., Ciccullo A., Baldin G., Cauda R., Fabbiani M., Di Giambenedetto S. Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients // HIV Research and Clinical Practice. 2019. Vol. 20. No. 3. pp. 92-98.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1080/25787489.2019.1653512
UR - https://doi.org/10.1080/25787489.2019.1653512
TI - Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients
T2 - HIV Research and Clinical Practice
AU - Lombardi, Francesca
AU - Belmonti, Simone
AU - Borghetti, Alberto
AU - Ciccullo, Arturo
AU - Baldin, Gianmaria
AU - Cauda, Roberto
AU - Fabbiani, Massimiliano
AU - Di Giambenedetto, Simona
PY - 2019
DA - 2019/05/04
PB - Taylor & Francis
SP - 92-98
IS - 3
VL - 20
PMID - 31478469
SN - 2578-7489
SN - 2578-7470
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2019_Lombardi,
author = {Francesca Lombardi and Simone Belmonti and Alberto Borghetti and Arturo Ciccullo and Gianmaria Baldin and Roberto Cauda and Massimiliano Fabbiani and Simona Di Giambenedetto},
title = {Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients},
journal = {HIV Research and Clinical Practice},
year = {2019},
volume = {20},
publisher = {Taylor & Francis},
month = {may},
url = {https://doi.org/10.1080/25787489.2019.1653512},
number = {3},
pages = {92--98},
doi = {10.1080/25787489.2019.1653512}
}
Cite this
MLA
Copy
Lombardi, Francesca, et al. “Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients.” HIV Research and Clinical Practice, vol. 20, no. 3, May. 2019, pp. 92-98. https://doi.org/10.1080/25787489.2019.1653512.